OverviewSuggest Edit

Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

TypePublic
Founded2010
HQRedwood City, CA, US
Websitecoherus.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Mar 2020)296(+2%)
Job Openings46
Revenue (FY, 2020)$475.8 M(+34%)
Share Price (May 2021)$14.3(-6%)
Cybersecurity ratingDMore

Key People/Management at Coherus BioSciences

Dennis M. Lanfear

Dennis M. Lanfear

President, CEO & Chairman
James Healy

James Healy

Director
Jean-Frederic Viret

Jean-Frederic Viret

Chief Financial Officer
V. Bryan Lawlis

V. Bryan Lawlis

Director
Vladimir Vexler

Vladimir Vexler

Chief Scientific Officer
Alan C. Mendelson

Alan C. Mendelson

Director
Show more

Coherus BioSciences Office Locations

Coherus BioSciences has offices in Redwood City and Camarillo
Redwood City, CA, US (HQ)
333 Twin Dolphin Dr #600
Camarillo, CA, US
1000 Avenida Acaso
Show all (2)

Coherus BioSciences Financials and Metrics

Coherus BioSciences Revenue

Coherus BioSciences's revenue was reported to be $475.8 m in FY, 2020
USD

Revenue (Q1, 2021)

83.0m

Gross profit (Q1, 2021)

75.5m

Gross profit margin (Q1, 2021), %

91%

Net income (Q1, 2021)

(172.9m)

EBIT (Q1, 2021)

(167.4m)

Market capitalization (7-May-2021)

1.0b

Closing stock price (7-May-2021)

14.3

Cash (31-Mar-2021)

259.5m

EV

868.5m
Coherus BioSciences's current market capitalization is $1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

31.1m30.0m190.1m1.6m356.1m475.8m

Revenue growth, %

(3%)533%

Cost of goods sold

37.7m

Gross profit

438.1m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

12.4m14.1m161.0k1.4m37.1m83.4m111.7m116.2m135.7m113.6m83.0m

Cost of goods sold

2.2m601.0k7.5m

Gross profit

34.9m82.8m75.5m

Gross profit Margin, %

94%99%91%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

150.4m158.2m124.9m126.9m72.4m177.7m541.2m

Accounts Receivable

142.0m157.0m

Prepaid Expenses

18.4m83.0k5.0m5.6m

Inventories

1.9m1.7m9.8m44.2m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m135.6m82.0m130.0m101.2m81.5m105.9m165.1m193.3m224.6m292.5m259.5m

Accounts Receivable

2.0m1.5m540.0k1.2m419.0k419.0k26.0k46.5m77.4m89.6m167.5m172.5m160.7m140.4m

Prepaid Expenses

18.0m20.1m27.0m31.7m26.0m15.0m16.6m30.5m34.2m21.1m32.0k145.0k179.0k5.6m5.2m3.1m6.4m5.5m5.6m10.4m

Inventories

2.3m4.3m7.7m16.4m27.2m35.2m51.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(87.2m)(223.9m)(127.8m)(238.3m)(209.4m)89.8m132.2m

Depreciation and Amortization

674.0k3.0m3.4m3.2m

Inventories

(5.5m)(48.2m)(36.2m)

Accounts Payable

3.6m(5.0m)(3.8m)(301.0k)9.9m(9.8m)
USDQ3, 2014

Financial Leverage

-0.8 x
Show all financial metrics

Coherus BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

D

64/100

SecurityScorecard logo

Coherus BioSciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Coherus BioSciences Online and Social Media Presence

Embed Graph

Coherus BioSciences News and Updates

Coherus BioSciences to Present at the Bank of America Health Care Conference

REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST.

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET, Coherus’ management t…

Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be f…

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic…

Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus…
Show more

Coherus BioSciences Frequently Asked Questions

  • When was Coherus BioSciences founded?

    Coherus BioSciences was founded in 2010.

  • Who are Coherus BioSciences key executives?

    Coherus BioSciences's key executives are Dennis M. Lanfear, James Healy and Jean-Frederic Viret.

  • How many employees does Coherus BioSciences have?

    Coherus BioSciences has 296 employees.

  • What is Coherus BioSciences revenue?

    Latest Coherus BioSciences annual revenue is $475.8 m.

  • What is Coherus BioSciences revenue per employee?

    Latest Coherus BioSciences revenue per employee is $1.6 m.

  • Who are Coherus BioSciences competitors?

    Competitors of Coherus BioSciences include Amgen, Landos Biopharma and NantKwest.

  • Where is Coherus BioSciences headquarters?

    Coherus BioSciences headquarters is located at 333 Twin Dolphin Dr #600, Redwood City.

  • Where are Coherus BioSciences offices?

    Coherus BioSciences has offices in Redwood City and Camarillo.

  • How many offices does Coherus BioSciences have?

    Coherus BioSciences has 2 offices.